Seelaus Asset Management LLC Trims Stock Position in Avantor, Inc. (NYSE:AVTR)

Seelaus Asset Management LLC decreased its holdings in shares of Avantor, Inc. (NYSE:AVTR) by 11.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,215 shares of the company’s stock after selling 1,550 shares during the quarter. Seelaus Asset Management LLC’s holdings in Avantor were worth $316,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its position in shares of Avantor by 2,003.6% during the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock worth $25,000 after purchasing an additional 1,102 shares during the period. Blue Trust Inc. lifted its stake in Avantor by 1,830.3% during the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after purchasing an additional 1,391 shares in the last quarter. UMB Bank n.a. purchased a new position in shares of Avantor during the third quarter worth $49,000. Nisa Investment Advisors LLC grew its stake in shares of Avantor by 69.6% in the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock valued at $53,000 after buying an additional 835 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Avantor by 89.9% in the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock valued at $70,000 after buying an additional 1,285 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Avantor Price Performance

Shares of NYSE AVTR opened at $20.75 on Friday. The stock has a market cap of $14.12 billion, a P/E ratio of 45.11, a P/E/G ratio of 2.61 and a beta of 1.35. Avantor, Inc. has a twelve month low of $19.11 and a twelve month high of $28.00. The stock has a 50 day moving average of $24.52 and a two-hundred day moving average of $24.01. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84.

Analysts Set New Price Targets

A number of brokerages recently commented on AVTR. UBS Group lowered their target price on Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, October 8th. Wells Fargo & Company lowered their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. Morgan Stanley increased their target price on shares of Avantor from $28.00 to $29.00 and gave the stock an “overweight” rating in a report on Monday, July 29th. Robert W. Baird dropped their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Finally, TD Cowen boosted their target price on Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $27.57.

Insider Activity

In related news, CAO Steven W. Eck sold 3,525 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the transaction, the chief accounting officer now owns 29,544 shares of the company’s stock, valued at $740,372.64. This trade represents a 10.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 1.50% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.